StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) income statement

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$31.77−0.75 (-2.31%)

Close on Nov 20, 2026Market cap $6.56BP/E –Yield –

See a number that looks wrong?